Literature DB >> 2153198

Radiopharmaceutical factors in the variable quality of [99mTc]HM-PAO images of the brain.

J R Ballinger1, K Y Gulenchyn, R H Reid.   

Abstract

Variability in the quality of [99mTc]HM-PAO images of the brain has been attributed to differences between kits and the addition of excessive amounts of pertechnetate to the kits. A retrospective study showed no significant differences between batches of kits with respect to radiochemical purity (RCP) or image quality. Up to 3000 MBq (81 mCi) pertechnetate could be added to the kit without adversely affecting RCP or image quality. It was shown that image quality was directly affected by RCP at time of injection and dropped sharply when RCP fell below 85%. Interstitial injection and mixing with blood prior to injection also resulted in poor image quality. Pretreatment with perchlorate reduced uptake of activity in the parotid glands; this improved image quality and reduced the influence of RCP.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153198

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  3 in total

1.  Technetium-99m exametazime (99mTc-HMPAO)-labeled white blood cells: a high efficiency multidose procedure.

Authors:  K Ozker; B D Collier; R S Hellman; A T Isitman; F Uzum; F G Steffel
Journal:  Eur J Nucl Med       Date:  1995-02

2.  Outcomes of patients referred for confirmation of brain death by 99mTc-exametazime scintigraphy.

Authors:  James W Harding; Barry E Chatterton
Journal:  Intensive Care Med       Date:  2003-03-25       Impact factor: 17.440

Review 3.  Consequences of radiopharmaceutical extravasation and therapeutic interventions: a systematic review.

Authors:  Jochem van der Pol; Stefan Vöö; Jan Bucerius; Felix M Mottaghy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-16       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.